A Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, First In Human Study of Orally Administered EDP-235 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses, Multiple Ascending Doses, and the Effect of Food on EDP-235 Pharmacokinetics in Healthy Participants
Latest Information Update: 17 Mar 2023
Price :
$35 *
At a glance
- Drugs EDP-235 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; First in man
- Sponsors Enanta Pharmaceuticals
- 14 Mar 2023 According to a Enanta Pharmaceuticals media release, company will have one oral presentation and three poster presentations.
- 14 Mar 2023 According to a Enanta Pharmaceuticals media release, results of this study are being presented at the 36th International Conference on Antiviral Research (ICAR) Tuesday, March 14 and Wednesday, March 15 at the Centre de Congres de Lyon (Lyon Convention Center) in Lyon, France.
- 14 Mar 2023 Results presented in an Enanta Pharmaceuticals media release.